C12N 2830/007
Cell cycle specific enhancer/promoter combination
Official title: cell cycle specific enhancer/promoter combination
C12N2830/007 (Cell cycle specific enhancer/promoter combination) appears on 53 US grants and 91 published applications in this corpus.
Search patents in C12N- Granted patents
- 53
- Published applications
- 91
- Assignees
- 47
- Inventors
- 155
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 4 | 0 |
| 2001 | 2 | 1 |
| 2002 | 3 | 4 |
| 2003 | 2 | 4 |
| 2004 | 0 | 3 |
| 2005 | 1 | 1 |
| 2006 | 3 | 2 |
| 2007 | 0 | 3 |
| 2008 | 0 | 3 |
| 2009 | 1 | 2 |
| 2010 | 0 | 1 |
| 2011 | 1 | 0 |
| 2012 | 1 | 0 |
| 2013 | 0 | 2 |
| 2014 | 0 | 2 |
| 2015 | 4 | 3 |
| 2016 | 1 | 4 |
| 2017 | 2 | 4 |
| 2018 | 2 | 9 |
| 2019 | 4 | 6 |
| 2020 | 1 | 6 |
| 2021 | 4 | 9 |
| 2022 | 3 | 5 |
| 2023 | 2 | 5 |
| 2024 | 4 | 3 |
| 2025 | 0 | 7 |
| 2026 | 7 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Gene-therapy vectors for treating cardiomyopathy29 Sep 2026US 12,747,453 B2
- Integration of nucleic acid constructs into eukaryotic cells with a transposase from oryzias22 Sep 2026US 12,742,171 B2Dna Twopointo Inc.
- Gene-therapy vectors for treating cardiomyopathy22 Sep 2026US 12,742,181 B2
- Recombinant adeno-associated viral vectors for delivering a therapeutic gene to lungs30 Jun 2026US 12,668,817 B1Telomere Therapeutics S.L.
- Systems and uses thereof for creating synthetic transcriptional logic ‘and’ gates based on pre-mRNA trans-splicing2 Jun 2026US 12,644,130 B2Migal Galilee Research Institute Ltd.
- Transposition of nucleic acid constructs into eukaryotic genomes with a transposase from amyelois10 Sep 2026US 2026/0265773 A1Dna Twopointo Inc.
- Gm3 synthase vectors and uses thereof23 Jul 2026US 2026/0209721 A1The Clinic for Special Children, Inc.
- Vectorized anti-tnf-alpha inhibitors for ocular indications18 Sep 2025US 2025/0288697 A1REGENXBIO Inc.
- Use of endogenous aspartoacylase promoter elements for tissue-restricted expression of gene therapies14 Aug 2025US 2025/0255987 A1University of Massachusetts
- Human cone photoreceptor optogenetic constructs7 Aug 2025US 2025/0250311 A1Institute of Molecular and Clinical Ophthalmology Basel (Iob)
Most cited
By later US patents
- Hypolipidemic 1,4-benzothiazepine-1,1-dioxides63US 6,020,330 AHoechst Aktiengesellschaft · 2000
- Adenovirus vectors containing cell status-specific response elements and methods of use thereof43US 7,968,333 B2Cold Genesys, Inc. · 2011
- Nucleic acid construct for expressing active substances which can be activated by proteases, and preparation and use29US 6,670,147 B1Aventis Pharma Deutschland GmbH · 2003
- Oncolytic adenovirus28US 7,001,596 B1Onyx Pharmaceuticals, Inc. · 2006
- DNA vectors, transposons and transposases for eukaryotic genome modification22US 10,041,077 B2Dna2.0, Inc. · 2018